Grandeur Bio

Grandeur Bio is a clinical-stage biotechnology company focused on developing next-generation small molecule therapies for autoimmune and inflammatory diseases. Headquartered in San Diego, the company is led by a team of industry veterans with a track record of success in immunology drug development. Its lead program, GB-001, is a highly selective oral inhibitor of Tyrosine kinase 2 (TYK2) currently in Phase 1 clinical trials for the treatment of plaque psoriasis. By targeting the TYK2 pathway with high precision, Grandeur Bio aims to provide patients with more effective and safer oral treatment options compared to existing therapies. The company is backed by leading life science venture capital firms and is committed to advancing its pipeline to address significant unmet medical needs.